2 results
Approved WMORecruiting
To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.
Approved WMOPending
To determine the safety and tolerability and to establish a preliminary RP2D and/or an MTD or an MAD of MK-4464 administered via IV infusion as monotherapy and in combination with pembrolizumab IV infusion